Literature DB >> 21834323

Emotional vulnerability and coping styles for resolving decisional conflict.

Kanayo Umeh1, Lorraine Omari-Asor.   

Abstract

This investigation supplements the study by D. Bouckenooghe, K. Vanderheyden, S. Mestdagh, and S. van Laethem (2007) on the role of cognitive dispositions in coping patterns for resolving decisional conflict. Literature suggests emotional vulnerabilities may significantly affect decision making. Thus, the present authors assessed the role of trait anxiety and depression in decision coping styles as specified by I. L. Janis and L. Mann's (1977) conflict-theory model. The participants--100 young adults--completed the Taylor Manifest Anxiety Scale (J. A. Taylor, 1953), Beck's Depression Inventory (A. T. Beck, R. A. Steer, & G. M. Garbin, 1988), and the Melbourne Decision-Making Questionnaire (L. Mann et al., 1998), which measures 4 coping strategies: vigilance, buck-passing, procrastination, and hypervigilance. Hierarchical multiple regression analysis, controlling for demographic and lifestyle factors, revealed trait anxiety and depression as significant predictors of procrastination and hypervigilance. Depression failed to predict buck-passing but functioned as an important moderator variable whereby trait anxiety better predicted hypervigilance in nondepressed participants. Consistent with past research, emotional dispositions failed to predict vigilance. Overall, these findings implicate emotional vulnerabilities in the quality of decision making but raise important questions about their unique and conditional effects.

Entities:  

Mesh:

Year:  2011        PMID: 21834323     DOI: 10.1080/00223980.2011.565381

Source DB:  PubMed          Journal:  J Psychol        ISSN: 0022-3980


  1 in total

1.  Decisional conflict and vaccine uptake: cross-sectional study of 2012/2013 influenza season in Croatia.

Authors:  Ivančica Pavličević; Slavica Škrabić; Mario Malički; Ana Hrvojka Merćep; Matko Marušić; Ana Marušić
Journal:  Arch Med Sci       Date:  2015-08-11       Impact factor: 3.318

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.